Scandion Oncology announce change to its Executive Management
Maj Hedtjärn has decided to resign from her position as Chief Operating Officer and Head of R&D Operations. She will leave Scandion Oncology no later than December 31, 2022.Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, announces that Maj Hedtjärn, Chief Operating Officer, Head of R&D Operations and member of Executive Management, has decided to resign from her position to pursue new opportunities outside Scandion. Maj Hedtjärn will leave Scandion no later than December 31, 2022,